Table 2.
Selected Clinical Trials of VEGF-targeted therapy in combination with oncogene-targeted therapy (July 2017).
| Anti-angiogenic | Target Therapy | Phase | Indications | ClinicalTrials.gov Identifier |
|---|---|---|---|---|
| Bevacizumab | Trastuzumab | 2 | Stage IV metastatic breast cancer | NCT00428922 |
| Bevacizumab | Trastuzumab | 3 | Metastatic HER2+ breast cancer | NCT00391092 |
| Bevacizumab | Trastuzumab | 2 | Breast cancer | NCT01321775 |
| Bevacizumab | Trastuzumab | 2 | Metastatic HER2+ breast cancer | NCT00364611 |
| Bevacizumab | Trastuzumab | 2 | Metastatic HER2+ breast cancer | NCT00670982 |
| Bevacizumab | Trastuzumab | 2 | Metastatic HER2+ breast cancer | NCT00392392 |
| Bevacizumab | Trastuzumab | 2 | Metastatic breast cancer | NCT00405938 |
| Sorafenib | Trametinib | 1 | HCC | NCT02292173 |
| Sorafenib | Refametinib | 2 | HCC | NCT01204177 |
| Sorafenib | Refametinib | 2 | HCC RAS-mutated | NCT01915602 |
| Regorafenib | Refametinib | 1 | Neoplasm | NCT02168777 |
| Bevacizumab | Erlotinib | 3 | CRC | NCT00265824 |
| Bevacizumab | Erlotinib | 2 | NSCLC EGFR-mutated | NCT01562028 |
| Bevacizumab | Erlotinib | 2 | NSCLC EGFR-mutated | NCT01532089 |
| Regorafenib | Cetuximab | 1 | Advanced cancers | NCT02095054 |
| Sorafenib | Cetuximab | 2 | Squamos cell carcinoma of the Head and Neck | NCT00815295 |
| Sorafenib | Cetuximab | 2 | CRC | NCT00326495 |
| Bevacizumab | Trastuzumab | 3 | HER2-positive breast cancer | NCT00625898 |
| Pazopanib | Lapatinib | 2 | HER2-positive breast cancer | NCT00558103. |
CRC, colorectal cancer; EGFR, epiderma growth factor receptor; HCC, hepatocellular carcinoma; HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer.
For reference see https://clinicaltrials.gov.